Table 5.
The discriminative ability of the studied markers to differentiate liver cirrhosis cases from healthy controls and HCC from liver cirrhosis cases
| Variable | % | p value | |||
|---|---|---|---|---|---|
| Cutoff | AUC | SN | SP | ||
| Discriminative ability to differentiate LC cases from healthy controls | |||||
| Intermediate monocytes percentage | > 0.38 | 0.927 | 82.5 | 86.7 | < 0.001* |
| Hsa-miR-21-5p fold change | > 1.55 | 0.977 | 97.5 | 100 | < 0.001* |
| Hsa-miR-155-5p fold change | > 1.17 | 0.618 | 67.5 | 60 | NS |
| Hsa-miR-21-5p + hsa-miR-155-5p | – | 0.975 | 97.5 | 100 | < 0.001* |
| Intermediate monocytes percentage + hsa-miR-21-5p | – | 1.00 | 100 | 100 | < 0.001* |
| Intermediate monocytes percentage + hsa-miR-155-5p | – | 0.935 | 90 | 86.7 | < 0.001* |
| AFP (ng/mL) | > 5.9 | 0.777 | 62.5 | 73.3 | 0.002* |
| NLR | > 1.14 | 0.805 | 80.0 | 73.3 | 0.001* |
| LMR | < 5.09 | 0.813 | 90.0 | 66.7 | < 0.001* |
| Discriminative ability to differentiate HCC cases from LC | |||||
| Intermediate monocytes percentage | 0.65 | 0.741 | 87.2 | 52.5 | < 0.001* |
| Hsa-miR-21-5p fold change | > 7.3 | 0.8 | 74 | 45 | < 0.001* |
| Hsa-miR-155-5p fold change | > 1.8 | 0.7 | 72 | 48 | < 0.01* |
| Hsa-miR-21-5p + hsa-miR-155-5p | – | 0.807 | 84.6 | 45 | < 0.001* |
| Intermediate monocytes percentage + hsa-miR-21-5p | – | 0.844 | 79.5 | 75 | < 0.001* |
| Intermediate monocytes percentage + hsa-miR-155-5p | – | 0.766 | 76.9 | 75 | < 0.001* |
| AFP (ng/mL) | > 23.3 | 0.85 | 69 | 100 | < 0.001* |
AFP alpha-feto protein, AUC area under the curve, SN sensitivity, SP specificity
*Significance at p < 0.05 level (2-tailed)